Study of Fluoxetine in Adults With Autistic Disorder

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00027404
Recruitment Status : Completed
First Posted : December 7, 2001
Last Update Posted : March 25, 2015
Information provided by:
FDA Office of Orphan Products Development

December 5, 2001
December 7, 2001
March 25, 2015
September 2001
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00027404 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Study of Fluoxetine in Adults With Autistic Disorder
Fluoxetine vs Placebo in Adult Autistic Disorder
This is a study to determine the effect of fluoxetine in the treatment of adult autism and on functional ability and behavior associated with autism. Evidence suggests abnormal serotonin function in autism. Fluoxetine is a selective inhibitor of the serotonin transporter.

Eligible patients will undergo comprehensive evaluation. Informants familiar with the patient will also provide information. Patients will be randomized to receive treatment or placebo. During the 12-week treatment there will be weekly monitoring for the first 4 weeks and biweekly monitoring for the next 8 weeks. The drug dosage will be increased each week as tolerated by the patient. Serum levels of fluoxetine and norfluoxetine will be documented at Week 12.

Completion date provided represents the completion date of the grant per OOPD records

Not Applicable
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Autistic Disorder
Drug: Fluoxetine
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
August 2005
Not Provided

Inclusion criteria:

  • Meets DSM-IV and ADI criteria for autistic disorder
  • Patients must use effective contraception
  • Negative pregnancy test
  • Clinical Global Impression-Severity Scale for Autistic Disorder (CGI-AD) score of 4

Exclusion criteria:

  • Pregnant or nursing
  • Prior or concurrent history of mental disorders, including schizophrenia, schizoaffective disorder, organic mental disorders, or bipolar disorders
  • Concurrent depression determined by DSM-IV diagnosis
  • Serious suicidal risk
  • Active seizure disorder within the past 2 years
  • Clinically significant or unstable medical illness, including hematopoietic or cardiovascular disease
  • Any organic or systemic disease
  • Any geographical condition that would preclude study compliance
  • Prior or concurrent gastrointestinal, liver, or kidney disease
  • Any other concurrent condition that interferes with the absorption, distribution, metabolism, or excretion of drugs
  • Prior or concurrent cerebrovascular disease or brain trauma
  • Prior or concurrent clinically significant unstable endocrine disorder, such as hypo- or hyperthyroidism
  • Prior or concurrent malignancy
  • Clinically significant abnormalities on EKG, laboratory tests, or physical exam
  • Requirement for ECT or any other psychotropic medication
  • Inability to tolerate taper from psychoactive medication
  • History of hypersensitivity or severe side effects associated with the use of fluoxitine or other serotonin reuptake inhibitors
  • Treatment with any drug known to have a well-defined potential for toxicity to a major organ within the past 30 days
  • Concurrent terfenadine (Seldane) or astemizole (Hismanal)
  • Prior treatment with fluoxetine of 40 mg/day for 6 weeks
  • Prior electroconvulsive therapy within the past 3 months
  • Prior investigational drug use within the past 30 days
  • Prior Monoamine oxidase inhibitor use within the past 14 days
  • Prior long-acting phenothiazines within the past 6 weeks
  • Prior psychotropic drugs within the past 7 days
  • Prior fluoxetine within the past 6 weeks
  • Requirement for any therapeutic intervention that would confound study evaluation
Sexes Eligible for Study: All
18 Years to 65 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Not Provided
Not Provided
Icahn School of Medicine at Mount Sinai
Not Provided
Principal Investigator: Eric Hollander, MD Mount Sinai School of Medicine New York, New York, United States
FDA Office of Orphan Products Development
November 2002

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP